

## PRODUCT INFORMATION

|   |  |
|---|--|
| <b>Clone ID</b>                         | DM74   |
| <b>Target</b>                           | Trop2  |
| <b>Synonyms</b>                         | TACSTD2; GA733-1; M1S1; TROP2  |
| <b>Host Species</b>                     | Rabbit   |
| <b>Description</b>                      | Biotinylated Anti-Trop2 antibody(DM74); Rabbit mAb   |
| <b>Delivery</b>                         | 2-3 weeks  |
| <b>Uniprot ID</b>                       | P09758   |
| <b>IgG type</b>                         | Rabbit IgG   |
| <b>Clonality</b>                        | Monoclonal   |
| <b>Reactivity</b>                       | Human  |
| <b>Applications</b>                     | ELISA; Flow Cyt  |
| <b>Recommended Dilutions</b>            | ELISA 1:5000-10000; Flow Cyt 1:100   |
| <b>Purification</b>                     | Purified from cell culture supernatant by affinity chromatography  |
| <b>Formulation &amp; Reconstitution</b> | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.   |
| <b>Storage&amp;Shipping</b>             | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.                    |
| <b>Background</b>                       | This intronless gene encodes a carcinoma-associated antigen. This antigen is a cell surface receptor that transduces calcium signals. Mutations of this gene have been associated with gelatinous drop-like corneal dystrophy.   |
| <b>Usage</b>                            | Research use only  |
| <b>Conjugate</b>                        | Biotinylated   |
| <b>DIMA Disclaimer</b>                  | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement. |

